ÐÇ¿ÕÓéÀÖ¹ÙÍø

Outcome data on infants born to women with hepatitis B virus (HBV) infection are collected, analyzed, and reported by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Perinatal Hepatitis B Prevention Program (PHBPP),¹ which funds 64 jurisdictions to identify pregnant women infected with HBV and to manage the health care of their infants to improve receipt of post-exposure prophylaxis (hepatitis B vaccine birth dose and hepatitis B immune globulin), hepatitis B vaccine series completion, and post-vaccination serologic testing.

Participating jurisdictions are the 50 US states, District of Columbia, five cities (Chicago, Houston, New York City, Philadelphia, and San Antonio), five territories (American Samoa, Guam, N. Mariana Islands, Puerto Rico, U.S. Virgin Islands), and three freely associated island nations (Federated States of Micronesia, Republic of the Marshall Islands, Republic of Palau). Data in this report are from the reporting period for the 2020 birth cohort, followed from January 1, 2020–December 31, 2021, and only include infants whose care was managed by the program.

Follow-up time for infants vary in length depending on their date of birth. Because of differences in the states and jurisdictions participating, not all cases in infants identified as HBsAg positive within the PHBPP are reported to the ÐÇ¿ÕÓéÀÖ¹ÙÍø National Notifiable Diseases Surveillance System (NNDSS).